ACRX
Closed
Acelrx Pharmaceuticals Inc
1.1277
+0.0277 (+2.52%)
Last Update: 12 Mar 2024 16:30:00
Yesterday: 1.1
Day's Range: 1.08 - 1.21
Send
sign up or login to leave a comment!
When Written:
0.655
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company that develops and commercializes innovative therapies for the treatment of acute pain. The company's lead product, DSUVIA, is a sublingual tablet formulation of sufentanil, a potent opioid analgesic, that is designed for rapid relief of moderate-to-severe acute pain in medically supervised settings. DSUVIA was approved by the U.S. Food and Drug Administration (FDA) in November 2018 and is currently marketed in the United States. AcelRx is also developing Zalviso, a system for patient-controlled analgesia in hospitals, and ARX-04, a non-opioid analgesic for the treatment of moderate-to-severe acute pain. The company is headquartered in Redwood City, California.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








